Search results
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 7 days agoAccording to leading data and analytics company GlobalData’s...reduce exacerbations and manage the...
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Morningstar· 5 days agoSociety (ATS) 2024 International Conference taking place May 12-22 in San Diego. "We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024
Earnings call: Regeneron reports steady growth, prepares for new launches By Investing.com
Investing.com· 3 days agoThis growth was primarily driven by strong sales of Dupixent and Libtayo, as well as collaboration...
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 4 days agoRegeneron stock is forming a flat base with a buy point at 998.33, according to MarketSurge. That's...
Mesothelioma
Health· 3 days agoRelated conditions include: Chronic obstructive pulmonary disease (COPD): Affects your breathing ability and blocks airflow Coronary artery disease...
Plant-based diet may reduce risk of emphysema among smokers - UPI.com
UPI· 7 days agoCurrent and former smokers might lower their risk for emphysema if they adopt a highly nutritional...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 3 days agoRegeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi's sBLA for Dupixent for COPD treatment was accepted by the FDA for priority review, highlighting ...
AstraZeneca to present respiratory disease research at ATS 2024 By Investing.com
Investing.com· 5 days agoDiego, California. The pharmaceutical company announced today that it will showcase 59 abstracts,...
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
